You are herePharma News

Pharma News


Herbalife launches third phase of Casa Herbalife program with smile foundation

(NewsVoir); The Herbalife Family Foundation (HFF), a non-profit organization dedicated to improving the lives of children by helping charitable organizations provide healthy nutrition to children in need, today announced the launch of the third phase of Casa Herbalife program with Smile Foundation, a national development organization that works for underprivileged children and youth in education, healthcare, livelihoods and women’s empowerment. During the third phase unveiled today in Bangalore, the HFF will extend grants to provide nutritional support to 1,000 children across India, through Smile Foundation’s ‘Mission Education’ program.


Herbalife Launches Third Phase of Casa Herbalife Program with Smile Foundation

(NewsVoir); The Herbalife Family Foundation (HFF), a non-profit organization dedicated to improving the lives of children by helping charitable organizations provide healthy nutrition to children in need, today announced the launch of the third phase of Casa Herbalife program with Smile Foundation, a national development organization that works for underprivileged children and youth in education, healthcare, livelihoods and women’s empowerment. During the third phase unveiled today in Bangalore, the HFF will extend grants to provide nutritional support to 1,000 children across India, through Smile Foundation’s ‘Mission Education’ program.


Cipla appoints Umang Vohra and Prabir Jha to its management team

Cipla Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, is announced the appointment of Umang Vohra as Global Chief Financial and Strategy Officer and Prabir Jha as Global Chief People Officer effective 1st October 2015.


Pfizer completes acquisition of Hospira

~ Creates a leading Global Established Pharmaceutical (GEP) Business
~ Expected to be immediately accretive to adjusted diluted EPS  upon closing; $0.10-$0.12 accretion to adjusted diluted EPS expected in first full year after close with additional accretion anticipated thereafter.

Pfizer Inc. announced that it has completed its acquisition of Hospira, Inc.
“We are pleased that Hospira, the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, is now part of Pfizer. We want to welcome our new Hospira colleagues to Pfizer. We are excited to add their talents and proud of the shared commitment of all Pfizer colleagues to serving patients worldwide,” said Ian Read, chairman and chief executive officer, Pfizer. “We believe that through this transaction, we’ve created value for our shareholders by delivering incremental revenue and expected EPS growth in the near-term by strengthening our GEP business and positioning it for future growth.”


Soon only Registered Pharmacists will get licence for wholesale store

Drugs Technical Advisory Board (DTAB) recommended that only Registered Pharmacist may eligible for getting approval of wholesale license of medicines in 70th meeting of DTAB held on 18th August, 2015 at central drugs standard control organization (CDSCO).


Cipla to acquire 100% of generic businesses in US for $550M

~ Through the acquisition of InvaGen, Cipla gains scale in the US generics market with a strong manufacturing and R&D base, access to broad product portfolio and a strong customer base consisting of top wholesalers/retailers
~ Through the acquisition of Exelan, Cipla gains access to the government and institutional market in the US

Cipla, a global pharmaceutical company which uses technology and innovation to meet the everyday needs of all patients, today announced that its UK arm, Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc. The transaction being subject to certain closing conditions, is valued at $550 million and will be an all cash transaction. The combined revenue from these transactions is over $200 million for the year ended Dec 2014 and over $225 million in LTM June 2015.


Sun Pharma and Wockhardt recall their drugs from US market

Voluntary recall of a number of drugs have been initiated by Sun Pharma and Wockhardt from the US market due to different reasons.

Sun Pharma initiated voluntary recall of multiple lots of Bupropion Hydrochloride Extended-release Tablets USP (SR), 200 mg, 60-count bottle for "failed dissolution specification", while Wockhardt started recalling its Lisinopril Tablets USP, 5 mg and 20 mg for "CGMP violations".


Researchers find child's ability to group objects & assess their vocabulary

One-year-old infant's ability to group objects according to the names associated with them - as opposed to their appearance alone - offers a glimpse into how their vocabulary will develop by the time they are 18 months, shows a new study. The findings will appear in an upcoming issue of the open access journal Frontiers in Psychology.


Poverty can Adversely Affect Children's Cognitive Development

Growing in severe poverty can adversely affect children's brain development, new research has found. The study was published in the journal JAMA Pediatrics.


Novel Drug Reduce Cardiovascular Problems in Diabetic Patients

Ezetimibe can reduce the cardiovascular problems in diabetes patients, says a new study. The drug achieved greater reductions in LDL cholesterol than statins alone, resulting in lower risks of cardiovascular events in patients with diabetes and the benefits observed in diabetics were greater than in those without diabetes.